Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Australia / NCT06186141
Recruiting Phase 4

Nausea and Vomiting in Postoperative Paediatric Patients With Patient-Controlled Analgesia (PCA): Morphine vs Oxycodone

NCT06186141 · tracked via the Priya Life Science Australia tracker
Sponsor
Murdoch Childrens Research Institute
Phase
Phase 4
Started
2024-03-13
Last updated
2026-07-21

Condition(s) studied

Patient-Controlled Analgesia

Investigational drug(s) / intervention(s)

Morphine →Oxycodone →

Morphine: Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout

Oxycodone: Intravenous (IV) delivery via Patient Controlled Analgesia device (PCA) 20mcg/kg bolus to a maximum of 1mg with a 5-minute lockout

Study summary

POPCORN trial will compare the side effects and effectiveness of Morphine versus Oxycodone medication when prescribed for use as patient controlled analgesia (PCA) for pain relief for paediatric patients after-surgery. This trial is embedded into routine patient care using the hospital electronic medical record (EMR). Participants will be randomly assigned to either medication after they enrol in the study.

The main questions the POPCORN trial aims to answer are:

* 1\. Is there a difference in the usage of medication to treat nausea and vomiting for those who received oxycodone PCA versus morphine PCA for post-surgery pain relief?
* 2\. Is there a difference in side effects or pain relief needed between the two groups?

Study activities are as follows:

* Participants enrolled to study during their pre-operative consultation
* Participants are randomly assigned to morphine or oxycodone
* No further study-specific activities expected from participant after enrolment and randomisation
* Participant receives routine medical care as planned
* Clinicians record assessments as per routine care in electronic medical record (EMR)
* EMR data are extracted as trial data

Eligibility

Sex
ALL
Min age
6 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * Postoperative patients who are appropriate for a PCA including those aged 6 and above and up to age 18 years. * Those deemed appropriate for either morphine or oxycodone by their treating anaesthetist. * American Society of Anaesthesiologists (ASA) score 1-3 inclusive * Those whose parents or legal guardians have provided informed consent on the patient's behalf. Exclusion Criteria: * Any patients with an allergy, hypersensitivity, or contraindication to morphine or oxycodone. * Patients in the age group with significant intellectual disability or physical incapacity rendering them incapable of using the PCA device * ASA score 4 or above * Inability or unwillingness of parent or legal guardian to provide informed consent for the study.

Primary outcome measure(s)

  • Antiemetic use — From PCA attachment to 72 hours or 4 hours after ceasing PCA, whichever is first.
    Prescription incidence and administration of any of the following to participant: Granisetron, Ondansetron, Droperidol, Metoclopramide, Cyclizine, Dexamethasone, and Promethazine

Trial sites (1)

FacilityCityRegionStatus
The Royal Children's Hospital Melbourne Victoria Recruiting

More Murdoch Childrens Research Institute trials in Australia

Can Vitamin D Supplementation in the First Year of Life Prevent Food Allergy in Infants? The VITALITY Trial: Parts 1&2 Active, not recruiting
A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma. Recruiting
Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children Recruiting
Jack Jumper Ant Venom Immunotherapy Long-term Effectiveness Investigation Recruiting
Determining the Effectiveness of Working Out Dads to Reduce Mental Health Difficulties in Fathers of Young Children Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06186141 on ClinicalTrials.gov ↗ ← All trials in Australia